Enhancement of Emmetropization in Highly Hyperopic Infants

Status Completed

Clinical Trial Summary

Infants do not usually wear glasses because they usually do not need them to see clearly. Most infants are born with a moderate amount of farsightedness. Most infants then undergo a natural process called 'emmetropization' that reduces the amount of farsightedness. However, up to 10% of infants don't emmetropize and end up with very farsighted prescriptions. Farsighted infants must use extra focusing effort to see clearly, which may make their eyes cross and perhaps cause a "lazy eye". If infants avoid this effort and their vision stays blurred into childhood, they may develop two lazy eyes. Farsightedness in school-aged children makes reading and learning more difficult. New studies in animals and in humans show that infant eyes will emmetropize best if they have just a normal, moderate amount of farsightedness. The infant eye must be in this normal target zone in order to emmetropize. If a baby were given glasses with the full prescription to correct all of his farsightedness, the eyes would also be out of the target zone and would not receive any signal to grow. The best strategy might be to give a partial spectacle correction for the farsightedness, just enough to put them in the zone that is most effective for emmetropization. The purpose of this project is to determine if emmetropization can be enhanced in very farsighted babies. We will give them glasses with a partial correction and accommodative (eye focusing) training. The partial correction is an amount that is less than their full degree of farsightedness but enough to put them in the zone of effective emmetropization. As changes in farsightedness occur, the power of the glasses will be reduced to keep the farsightedness within the target zone. If an infant reaches a normal amount of farsightedness, the glasses will be discontinued. The comparison group will be farsighted babies who receive the current standard of care, namely no correction. The main outcome of the study will be whether there is a significant difference in the decrease of farsightedness between the two groups when the infants are 18 months of age. If emmetropization can be enhanced in very farsighted babies, the risk of developing crossed or lazy eye will be reduced. The lifelong need for spectacles, contact lenses, or refractive surgery for high amounts of farsightedness would also be reduced. Positive results might also make infant eye examinations more common and place a new therapeutic option in clinicians' hands.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hyperopia

Clinical Trial Details

NCT number	NCT03669146
Study type	Interventional
Source	Ohio State University
Contact
Status	Completed
Phase	N/A
Start date	April 24, 2019
Completion date	January 5, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06046209` - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens	N/A
Completed	`NCT05656885` - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses	N/A
Completed	`NCT02423109` - Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses	N/A
Completed	`NCT01392950` - Clinical Study of Clariti Monthly Contact Lens	N/A
Withdrawn	`NCT00765960` - Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure
Completed	`NCT00520689` - Multipurpose Disinfecting Solution Compatibility With a Silicone Hydrogel Contact Lens	Phase 3
Completed	`NCT05538182` - Zimbabwe Eyecare And Learning(ZEAL):Formative Research on Hyperopia and Educational Outcomes in Primary School Children	N/A
Enrolling by invitation	`NCT05976750` - Air Optix® Night and Day® Aqua Daily Wear
Completed	`NCT02575911` - Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study	N/A
Completed	`NCT05735990` - Retrospective Clinical Investigation of the Safety and Performance of 640PM Trifocal IOL Implantation in Patients With Cataract and/or Ametropia (Hyperopia, Myopia) and/or Presbyopia
Withdrawn	`NCT03671096` - Safety and Efficacy of the Transform™ Corneal Allograft for Hyperopia Correction	N/A
Recruiting	`NCT02279446` - Development of a Validated Chart for Intermediate Vision Assessment	N/A
Completed	`NCT01951573` - Evaluation of a New Daily Disposable Multifocal Contact Lens Design	N/A
Completed	`NCT02060539` - Multicenter Dispensing Study of Biofinity Lenses in Extended Range	N/A
Completed	`NCT01467557` - Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY
Completed	`NCT01228591` - Pilot Dispensing Evaluation of a Plus Power Lens	N/A
Completed	`NCT03722784` - Evaluation of Silicone Hydrogel Daily Wear Contact Lenses for Up to One (1) Month of Daily Wear	N/A
Completed	`NCT03688672` - Apioc Contact Lens Feasibility	N/A
Completed	`NCT05741450` - A Clinical Comparison of Two Soft Contact Lenses	N/A
Completed	`NCT01912781` - Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.